^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

Published date:
11/09/2021
Excerpt:
Immunohistochemistry confirmed expression of B7-H4 across multiple solid tumor types, including ovarian and breast tumors….In vivo, SGN-B7H4V demonstrated strong anti-tumor activity in multiple xenograft models, including ovarian and breast cancer models.
DOI:
http://dx.doi.org/10.1136/jitc-2021-SITC2021.854